Google
Trusted Resources: News & Events
Latest announcements and gatherings
First Sickle Cell Patient Dosed in Phase 2a of IMR-687
This morning, Imara Inc. announced that it has dosed the first patient in its Phase 2a clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of escalating doses of IMR-687 in adult patients with sickle cell disease (SCD).
In May, IMR-687 was granted Rare Pediatric Disease designation by the U.S. Food and Drug Administration (FDA), the first SCD product candidate to receive the label. The drug is being developed as a highly-potent oral therapy for once-daily dosing with the intention of addressing both the underlying red and white blood cell pathologies associated with the condition.
SCD is a severe, hereditary variation of anemia in which a mutated form of hemoglobin distorts the red blood cells at low oxygen levels into crescent-shaped cells that resemble a sickle. “IMR-687 is being rapidly advanced, as Imara is dosing the first eligible patient less than 2 years from the launch of the company.
+myBinderRelated Content
-
An analysis of inpatient pediatric sickle cell disease: Incidence, costs, and outcomesOBJECTIVE: To identify characteristics ...
-
Preoperative blood transfusions for sickle cell diseaseBackground: Sickle cell disease is one ...
-
La Jolla Pharmaceutical company announces initiation of pivotal clinical study of LJPC-401 in patients with beta tha...La Jolla Pharmaceutical company today an...
-
Potential treatment targeting nitric oxide levels, olinciguat, named orphan drug by FDAThe U.S. Food and Drug Administration ...
-
Using CRISPR Cas9 to cure sickle cell diseasehttps://www.youtube.com/watch?v=WdkP-RU5...
-
FDA agrees accelerated approval pathway for GBT’s voxelotorGlobal Blood Therapeutics, Inc. ...
-
Patient Perspective: Childhood Experiences of Sickle Cellhttps://www.youtube.com/watch?v=982zM-s4...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.